Fig. 6From: XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexorXPO1 inhibitor KPT-335 inhibits tumor growth in vivo. A photograph of sacrificed nude mice and xenograft. B Tumor volume and C weight of nude mice was reduced after KPT-335 treatment. D Immunohistochemistry showed XPO1, Ki67 and PCNA expression levels of xenograft tumor tissues was reduced (× 200). E No obvious pathological changes were found in the lung, liver, kidney and heart after KPT-335 treatment. Data presented as mean ± SD (n = 5). ** P < 0.01, *** P < 0.001Back to article page